Our policy and aims
Anthony Nolan works with pharmaceutical companies in a variety of ways and several policies, which are underpinned by operational procedures and due diligence, ensure these relationships are conducted ethically. We have an overarching policy in place which governs how we work with pharmaceutical companies in a commercial and non-commercial capacity. If a relationship is commercial, it is subject to our usual due diligence procedures for working with third parties and is always subject to a contractual framework. We always aim to be open, transparent, and honest in response to any public, supporter, patient or media enquiry concerning any of our relationships with pharmaceutical companies.
The total amount Anthony Nolan receives from the pharmaceutical industry in one financial year will not exceed 10% of our total income. If our income from the industry would exceed 10% by agreeing to additional funding from a company or companies, then such a decision would require specific approval from the Chief Executive and the Board of Trustees. The income Anthony Nolan has received from the pharmaceutical industry in FY 25/26 represents 1% of our total income (the same as the 1% of our total income in 24/25).
Anthony Nolan's non-commercial work with pharmaceutical companies in 2025/26
We would like to acknowledge the following non-commercial work with pharmaceutical companies in the last year:
- Autolus for grant funding of £20,000 towards our Healthcare Professionals CAR-T Online Training
- Gilead Sciences Limited for grant funding of £8,184 towards our CAR-T Health Care Professional Online E-Learning System; £3,640 towards our CAR-T Patent Experience Study; £15,000 towards our recruitment partnership with One Voice Blackburn and £30,000 towards our Patient Grants Programme.
- Johnson & Johnson for grant funding of £10,000 towards the printing of 8,000 Patient Information booklets.
- Sanofi for grant funding of £39,666 towards our Research Data Managers Programme, and for reimbursement for Rachel Miller’s speaking fee, to the value of £540
- Takeda UK Limited for grant funding of £10,000 towards our Donor Recruitment Programme.
- Therakos UK for grant funding of £70,000 towards our Patient Reported Outcomes Research, and $50,000 towards our Patient Grants Programme.
- Anthony Nolan is also a member of various coalitions which receive funding from the pharmaceutical industry, including the Blood Cancer Alliance, Cancer52 and the Specialist Healthcare Alliance. Pharmaceutical funders of these organisations are listed on their respective websites:
- Funding — Blood Cancer Alliance
- Cancer52 | Collaborations & Supporters
- shca.info/members-and-supporters